Company / Current Liabilities
Cue Biopharma, Inc. Current Liabilities History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$13.5M
FY2025
5-year range
$11.5M / $17.1M
FY2021-FY2025
Trend
-1.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 8 years, ranging from $6M in FY2018 to $17M in FY2023.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -3.7%.
Improved from $17M to $13M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +5.3%
- 5-Year CAGR
- -3.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.7%, indicating a declining trend.
- In FY2025, current liabilities decreased 1.4% year-over-year.
- Peak current liabilities was recorded in FY2023.
- Lowest current liabilities in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.5M | -1.4% |
| FY2024 | $13.7M | -19.9% |
| FY2023 | $17.1M | +47.9% |
| FY2022 | $11.5M | -9.7% |
| FY2021 | $12.8M | -21.6% |
| FY2020 | $16.3M | +40.0% |
| FY2019 | $11.7M | +87.5% |
| FY2018 | $6.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026